Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

Company Overview

Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.22 to $0.30
• 52-Week Range: $0.17 to $0.48
• Volume: 2.10 million shs
• Average Volume: 2.14 million shs
• Market Capitalization: $379.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NWBO Stock Analysis - Frequently Asked Questions

How have NWBO shares performed this year?

Northwest Biotherapeutics' stock was trading at $0.2748 at the beginning of the year. Since then, NWBO stock has decreased by 9.0% and is now trading at $0.25.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) posted its earnings results on Thursday, August, 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company earned $0.13 million during the quarter.

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NWBO
• Previous Symbol: NASDAQ:NWBO
• CIK: 1072379
• Web: www.nwbio.com
• Phone: (240) 497-9024
• Fax: 240-627-4121
• Employees: 20
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.78 million
• Net Margins: -7,524.50%
• Pretax Margin: -7,524.50%
• Return on Equity: N/A
• Return on Assets: -291.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $1.38 million
• Price / Sales: 275.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -3.57

Miscellaneous

• Outstanding Shares: 1,518,300,000
• Free Float: 1,386,207,000
• Market Cap: $379.58 million
• Optionable: Not Optionable
• Beta: -0.70